A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)

NCT00314574 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

850

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: omalizumab (Xolair)
DRUG: placebo
DRUG: corticosteroids
DRUG: long-acting beta-agonists

Sponsor

Genentech, Inc.